June 8, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced completion of patient accrual in its Phase 3 REVELATE clinical trial of 18F-fluciclovine, a
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now
